Pragmatic Clinical Trial Resources-Conducting Pragmatic Clinical Trials

Conducting Pragmatic Clinical Trials – Pitfalls & Pearls

Pdf Summary

Pragmatic clinical trials (PCTs) are designed to test how well interventions work in routine, real-world clinical practice, contrasting with explanatory trials that assess efficacy under tightly controlled conditions. PCTs aim to inform real decision-makers (patients, clinicians, policy makers) and to enroll populations and sites representative of usual care. They offer advantages over observational real-world evidence by improving generalizability while preserving randomization, enabling faster evidence generation and better inclusion of diverse and underrepresented groups.<br /><br />The talk highlights that oncology trials are increasingly complex and expensive; pivotal oncology trials have averaged tens of millions of dollars, with major cost drivers including extra procedures, packaging and placebo logistics, pharmacovigilance, regulatory requirements, and especially on-site monitoring. Tools such as PRECIS-2 help investigators position a study along the pragmatic–explanatory continuum across key design domains (setting, eligibility, follow-up, outcomes, analysis, etc.).<br /><br />Key pitfalls of PCTs include: excessive heterogeneity, variable adherence, and co-interventions that can dilute true effects (risking type II error); weaker internal validity due to confounding, contamination, and bias; loss to follow-up and missing data in routine care; limited blinding and variable implementation fidelity; larger sample size needs and complex statistical methods (including cluster designs); and risks from post-hoc subgroup analyses. Ethical and regulatory challenges arise from blurred boundaries between care and research and the difficulty of obtaining meaningful consent in embedded designs. Reliance on EHR/administrative data can create data quality issues, alongside governance and privacy concerns. There may also be skepticism about rigor, publication bias for null results, and operational complexity.<br /><br />A prostate cancer example (PIVOT) illustrates how underpowering, outdated comparators, and risk-mix dilution can produce misleading “negative” conclusions.<br /><br />Practical “pearls” include choosing a clinically urgent, tolerably sized question; adopting hybrid designs with selective explanatory “anchors”; minimizing disruption to workflows and extra tests; keeping eligibility broad where safe; selecting patient-relevant, routinely captured endpoints; simplifying randomization and follow-up; building multidisciplinary and statistical expertise early; maintaining robust consent practices; piloting before scaling; and learning iteratively. PRAGMATICA-LUNG is presented as a pragmatic case study using broad eligibility and streamlined data to support clinically meaningful, potentially regulatory-grade outcomes.

Keywords

pragmatic clinical trials

real-world evidence

randomization in routine care

oncology trial cost drivers

on-site monitoring

PRECIS-2 tool

pragmatic–explanatory continuum

EHR and administrative data quality

ethical and regulatory consent challenges

PRAGMATICA-LUNG study